Sacituzumab govitecan-hziy (intravenous route)

Trodelvy

Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease. Sacituzumab govitecan-hziy injection is also used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced) in patients who have received endocrine treatment and at least 2 treatments for metastatic disease. Sacituzumab govitecan-hziy injection is also used to treat urothelial cancer (bladder cancer and cancer of the urinary tract) that has spread or cannot be removed by surgery in patients who have received other cancer medicines (eg, immunotherapy medicine, platinum-containing cancer medicine). Sacituzumab govitecan-hziy belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Some of these may be serious and must be reported to your doctor. This medicine is to be given only by or under the immediate supervision of your doctor. This product is available in the following dosage forms:

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Appropriate studies have not been performed on the relationship of age to the effects of sacituzumab govitecan-hziy injection in the pediatric population. Safety and efficacy have not been established. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of sacituzumab govitecan-hziy injection in the elderly. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: